A novel compound to induce weight loss and reduce binge drinking

In recent years, weight loss drugs that target the glucagon-like peptide-1 (GLP-1) system have become blockbuster treatments, and they are now being repurposed for a wide range of indications. One of these is alcohol use disorder (AUD), with 20 clinical trials currently underway assessing GLP-1-based treatments for AUD. While there have been positive studies, efficacy is variable and adverse effects are common, which can be limiting. We have addressed these issues in a creative and innovative manner by conjugating GLP-1 to a second molecule, essentially using GLP-1 as a chaperone to deliver the second molecule for circuit-specific polypharmacy. Indeed, we have compelling proof-of-concept data that such molecules reduce alcohol intake with good efficacy and a lack of adverse outcomes.

This program involves medicinal chemistry, in vivo behavioural neuropharmacology in animal models plus in vitro mechanistic studies in cell-based systems.